Management  	Management  	 NN	O
of  	of  	 IN	O
anticoagulation  	anticoagulation  	 NN	B-NP
and  	and  	 CC	O
antiplatelet  	antiplatelet  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
left  	left  	 VBN	O
ventricular  	ventricular  	 RB	O
assist  	assist  	 VB	O
devices  	devices  	 NNS	O
Left  	Left  	 VBD	B-NP
ventricular  	ventricular  	 RB	I-NP
assist  	assist  	 VB	I-NP
devices  	devices  	 NNS	I-NP
( 	( 	 -LRB-	O
LVADs 	LVADs 	 NNP	B-NP
)  	)  	 -RRB-	O
have  	have  	 VBP	O
increased  	increased  	 VBN	O
the  	the  	 DT	O
survival  	survival  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
advanced  	advanced  	 JJ	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
fourfold 	fourfold 	 NN	O
.  	.  	 .	O
Despite  	Despite  	 IN	O
these  	these  	 DT	O
advances 	advances 	 NNS	O
,  	,  	 ,	O
significant  	significant  	 JJ	O
bleeding  	bleeding  	 NN	O
and  	and  	 CC	O
thrombotic  	thrombotic  	 JJ	B-NP
complications  	complications  	 NNS	I-NP
occur 	occur 	 VBP	O
.  	.  	 .	O
Hemorrhage  	Hemorrhage  	 RB	B-NP
requiring  	requiring  	 VBG	I-NP
surgery  	surgery  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
reported  	reported  	 VBN	O
in  	in  	 IN	O
up  	up  	 RB	O
to  	to  	 TO	O
30 	30 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
adults  	adults  	 NNS	O
and  	and  	 CC	O
50 	50 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
children  	children  	 NNS	O
after  	after  	 IN	O
LVAD  	LVAD  	 NNP	B-NP
placement 	placement 	 NN	I-NP
.  	.  	 .	O
LVAD  	LVAD  	 NNP	B-NP
thrombosis  	thrombosis  	 NN	I-NP
and  	and  	 CC	O
embolic  	embolic  	 JJ	B-NP
stroke  	stroke  	 NN	I-NP
lead  	lead  	 NN	I-NP
to  	to  	 TO	O
significant  	significant  	 JJ	O
long-term  	long-term  	 JJ	O
morbidity 	morbidity 	 NN	O
.  	.  	 .	O
Adults  	Adults  	 NNS	O
are  	are  	 VBP	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
antithrombotic  	antithrombotic  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
to  	to  	 TO	O
prevent  	prevent  	 VB	O
thrombotic  	thrombotic  	 JJ	B-NP
complications 	complications 	 NNS	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
the  	the  	 DT	O
amount  	amount  	 NN	O
and  	and  	 CC	O
intensity  	intensity  	 NN	O
of  	of  	 IN	O
treatment  	treatment  	 NN	O
differs  	differs  	 VBZ	O
between  	between  	 IN	O
institutions 	institutions 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
goal  	goal  	 NN	O
international  	international  	 JJ	O
normalized  	normalized  	 JJ	O
ratio  	ratio  	 NN	O
for  	for  	 IN	O
warfarin  	warfarin  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
varies  	varies  	 VBZ	O
from  	from  	 IN	O
1.5  	1.5  	 CD	O
to  	to  	 TO	O
3.0 	3.0 	 CD	O
.  	.  	 .	O
Some  	Some  	 DT	O
physicians  	physicians  	 NNS	O
manage  	manage  	 VBP	O
adult  	adult  	 JJ	O
LVAD  	LVAD  	 NN	B-NP
patients  	patients  	 NNS	I-NP
without  	without  	 IN	O
antiplatelet  	antiplatelet  	 JJ	B-NP
medication 	medication 	 NN	I-NP
,  	,  	 ,	O
whereas  	whereas  	 IN	O
other  	other  	 JJ	O
adults  	adults  	 NNS	O
are  	are  	 VBP	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
aspirin  	aspirin  	 NN	O
as  	as  	 IN	O
a  	a  	 DT	O
single  	single  	 JJ	O
agent  	agent  	 NN	B-NP
or  	or  	 CC	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
dipyridamole 	dipyridamole 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
contrast 	contrast 	 NN	O
,  	,  	 ,	O
physicians  	physicians  	 NNS	O
typically  	typically  	 RB	O
manage  	manage  	 VB	O
children  	children  	 NNS	O
with  	with  	 IN	O
LVADs  	LVADs  	 JJ	O
using  	using  	 VBG	O
the  	the  	 DT	O
Edmonton  	Edmonton  	 NNP	B-NP
Anticoagulation  	Anticoagulation  	 NNP	I-NP
and  	and  	 CC	O
Platelet  	Platelet  	 NNP	B-NP
Inhibition  	Inhibition  	 NNP	I-NP
Protocol 	Protocol 	 NNP	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
detailed  	detailed  	 JJ	O
algorithm  	algorithm  	 NN	B-NP
for  	for  	 IN	I-NP
anticoagulation  	anticoagulation  	 NN	I-NP
and  	and  	 CC	O
antiplatelet  	antiplatelet  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
modified  	modified  	 VBN	O
based  	based  	 VBN	O
on  	on  	 IN	O
thromboelastography  	thromboelastography  	 JJ	B-NP
results 	results 	 NNS	I-NP
.  	.  	 .	O
LVAD  	LVAD  	 NNP	B-NP
implantation  	implantation  	 NN	I-NP
causes  	causes  	 VBZ	O
consumption  	consumption  	 NN	O
of  	of  	 IN	O
coagulation  	coagulation  	 JJ	B-NP
proteins 	proteins 	 NNS	I-NP
,  	,  	 ,	O
activation  	activation  	 VBG	B-NP
of  	of  	 IN	I-NP
fibrinolysis 	fibrinolysis 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
loss  	loss  	 NN	O
of  	of  	 IN	O
high  	high  	 JJ	O
molecular  	molecular  	 JJ	B-NP
weight  	weight  	 NN	I-NP
von  	von  	 NNP	I-NP
Willebrand  	Willebrand  	 NNP	I-NP
protein  	protein  	 NN	I-NP
multimers 	multimers 	 NN	I-NP
.  	.  	 .	O
How  	How  	 WRB	O
these  	these  	 DT	O
changes  	changes  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
coagulation  	coagulation  	 JJ	B-NP
system  	system  	 NN	I-NP
influence  	influence  	 NN	I-NP
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
hemorrhage  	hemorrhage  	 NN	B-NP
and  	and  	 CC	O
initiation  	initiation  	 NN	O
of  	of  	 IN	O
thrombosis  	thrombosis  	 NN	O
is  	is  	 VBZ	O
unknown 	unknown 	 JJ	O
.  	.  	 .	O
Prospective 	Prospective 	 JJ	O
,  	,  	 ,	O
controlled  	controlled  	 VBN	B-NP
studies  	studies  	 NNS	I-NP
are  	are  	 VBP	O
needed  	needed  	 VBN	O
to  	to  	 TO	O
determine  	determine  	 VB	O
the  	the  	 DT	O
antithrombotic  	antithrombotic  	 JJ	B-NP
regimen  	regimen  	 NN	I-NP
that  	that  	 IN	O
most  	most  	 RBS	O
effectively  	effectively  	 RB	O
balances  	balances  	 JJ	O
bleeding  	bleeding  	 NN	O
and  	and  	 CC	O
thrombosis  	thrombosis  	 NN	O
in  	in  	 IN	O
LVAD  	LVAD  	 NNP	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
